Posted by Michael Wonder on 27 Sep 2019
With Brexit looming, what does the future hold for UK biosimilars?
26 September 2019 - If and when the United Kingdom leaves the European Union, the Medicines and Healthcare Products Regulatory Agency is poised to provide its own review structure for biosimilars.
During the SMi 10th Annual Biosimilars Conference, being held in London, United Kingdom, numerous speakers have noted that the United Kingdom has been a biosimilars success story.
With high uptake of anti–tumour necrosis factor therapies and policies that drive biosimilar adoption, the United Kingdom has led among nations in the EU5 in its biosimilar initiatives. However, as uncertainty about the UK withdrawal from the European Union grows deeper, and with the current October 31 deadline for Brexit looming, there remain serious questions about the future of UK biosimilars.
